Sebastian A. Brunemeier is a biotech founder and VC investor, focusing on the biology of ageing. Sebastian was previously a Principal at Apollo Health Ventures, the first and largest aging-focused venture capital fund in the world, as well as Co-Founder and Chief Investment Officer at Cambrian Biopharma, a biotech VC holding company focused on the biology of aging. Sebastian was CEO of Cyclone Therapeutics, a Scripps Research Institute spinout focused on proteostasis. He also was the founding EIR and COO of Samsara Therapeutics, focused on autophagy-enhancing small molecule drug discovery in Oxford, UK, which was recognized as ‘best startup’ at the Financial Times Pharma Conference. Prior to Apollo, he was a Fulbright Fellow in the biology of aging at the Gulbenkian Institute, awarded the Skaggs-Oxford fellowship at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. His education includes DPhil (PhD) training on the biochemistry of aging at the University of Oxford as a Clarendon Scholar, an MSc in Life Science Business Management and an MSc in Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. He served as a trustee of the British Society for Research on Aging and is an advisor to McKinsey & Company.

Surveying the underlying molecular and cellular neuroscience of brain ageing, in addition to a critique of currently fashionable themes in CNS drug discovery (with a focus on Alzheimer’s dementia).